29.08.2017

In der real world angekommen: NOAKs bewähren sich im Behandlungsalltag

3 Ärzte stehen zusammen, wobei die Frau in die Kamera lächelt

© stokkete / Fotolia

Quellen:

  1. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891. http://www.ncbi.nlm.nih.gov/pubmed/21830957
  2. Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992. http://www.ncbi.nlm.nih.gov/pubmed/21870978
  3. Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104. http://www.ncbi.nlm.nih.gov/pubmed/24251359
  4. Coleman CI et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 2016; 32: 2047-2053. https://www.ncbi.nlm.nih.gov/pubmed/27633045
  5. Camm AJ et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37: 1145-1153. https://www.ncbi.nlm.nih.gov/pubmed/26330425
  6. Tamayo S et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015; 38: 63-68. https://www.ncbi.nlm.nih.gov/pubmed/25588595
  7. Pressemitteilung zur DGK-Jahrestagung 2017. Moderne Schlaganfallprophylaxe bei VHF – Am Puls der Zeit. Daiichi Sankyo Deutschland GmbH, München, Deutschland, 2017.
  8. Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (ETNA-AF-EU). National Institute of Health Clinical trial database. https://clinicaltrials.gov/ct2/show/NCT02207257.
  9. Fachinformation LIXIANA®, Daiichi Sankyo Europe GmbH, München, Deutschland. Stand Juli 2017. http://fachinformation.srz.de/pdf/daiichisankyo/lixiana60mgfilmtabletten.pdf

INFORMATION FÜR FACHKRÄFTE

[DocCheckStop]